Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of BIIB132 in Spinocerebellar Ataxia 3
NCT05160558Phase 1Terminated
- Sponsor
- Biogen
- Start
- Feb 2022
- Primary completion
- Jul 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of BIIB132 in spinocerebellar ataxia type 3 (SCA3) (5 cohorts), sponsored by Biogen. Primary endpoints: Number of Participants with Adverse Events and Number of Participants with Serious Adverse Events. Started Feb 2022; status: terminated.
02
Drugs
BIIB132
03
Conditions
spinocerebellar ataxia type 3 (SCA3)
Beyond the preview
Go deeper on NCT05160558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160558.